Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Halank

Showing results (11-20 of 133) with videos related to

Pageof 14
Sort By:
Therapeutic Advances in Respiratory Disease|August 24, 2019
Practical management of riociguat in patients with pulmonary arterial hypertensionMichael Halank, Kristin Tausche, Ekkehard Grünig, et al.
Respirology (Carlton, Vic.)|August 8, 2009
Early recurrence of Pneumocystis jiroveci pneumonia in two HIV-infected patients: linking infection relapse and immune reconstitution syndromeMartin Kolditz, Michael Halank, Dirk Bandt, et al.
Respiratory Medicine|March 1, 2021
Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension - A review of the past, present and futureBeate Stubbe, Christian F Opitz, Michael Halank, et al.
Expert Opinion on Pharmacotherapy|August 12, 2009
Inhalative iloprost - pharmacology and clinical applicationRalf Ewert, Christoph Schäper, Michael Halank, et al.
Expert Review of Respiratory Medicine|November 30, 2021
Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertensionRalf Ewert, Dirk Habedank, Michael Halank, et al.
European Journal of Internal Medicine|August 12, 2020
Limited prognostic accuracy of the CRB-65 and qSOFA in patients presenting with pneumonia and immunosuppressionSophie Frantz, Bernhard Schulte-Hubbert, Michael Halank, et al.
Pneumologie (Stuttgart, Germany)|June 27, 2003
[Sildenafil in pulmonary hypertension]Ralf Ewert, Marius Höper, Michael Halank, et al.
Pulmonary Circulation|March 13, 2014
Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trialHans-Jürgen Seyfarth, Stefan Hammerschmidt, Michael Halank, et al.
Wiener Medizinische Wochenschrift (1946)|September 15, 2005
Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentanMichael Halank, Martin Kolditz, Stephan Miehlke, et al.
Respiration; International Review of Thoracic Diseases|April 27, 2022
Anxiety, Depression and Quality of Life in Pulmonary Hypertension: A Comparison of Incident and Prevalent CasesElena Pfeuffer-Jovic, Franziska Joa, Michael Halank, et al.
Pageof 14

Showing results (11-20 of 133) with videos related to

Sort By:
Pageof 14
Therapeutic Advances in Respiratory Disease|August 24, 2019
Practical management of riociguat in patients with pulmonary arterial hypertensionMichael Halank, Kristin Tausche, Ekkehard Grünig, et al.
Respirology (Carlton, Vic.)|August 8, 2009
Early recurrence of Pneumocystis jiroveci pneumonia in two HIV-infected patients: linking infection relapse and immune reconstitution syndromeMartin Kolditz, Michael Halank, Dirk Bandt, et al.
Respiratory Medicine|March 1, 2021
Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension - A review of the past, present and futureBeate Stubbe, Christian F Opitz, Michael Halank, et al.
Expert Opinion on Pharmacotherapy|August 12, 2009
Inhalative iloprost - pharmacology and clinical applicationRalf Ewert, Christoph Schäper, Michael Halank, et al.
Expert Review of Respiratory Medicine|November 30, 2021
Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertensionRalf Ewert, Dirk Habedank, Michael Halank, et al.
European Journal of Internal Medicine|August 12, 2020
Limited prognostic accuracy of the CRB-65 and qSOFA in patients presenting with pneumonia and immunosuppressionSophie Frantz, Bernhard Schulte-Hubbert, Michael Halank, et al.
Pneumologie (Stuttgart, Germany)|June 27, 2003
[Sildenafil in pulmonary hypertension]Ralf Ewert, Marius Höper, Michael Halank, et al.
Pulmonary Circulation|March 13, 2014
Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trialHans-Jürgen Seyfarth, Stefan Hammerschmidt, Michael Halank, et al.
Wiener Medizinische Wochenschrift (1946)|September 15, 2005
Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentanMichael Halank, Martin Kolditz, Stephan Miehlke, et al.
Respiration; International Review of Thoracic Diseases|April 27, 2022
Anxiety, Depression and Quality of Life in Pulmonary Hypertension: A Comparison of Incident and Prevalent CasesElena Pfeuffer-Jovic, Franziska Joa, Michael Halank, et al.
Pageof 14